Curis Q2 2026 Earnings Report

Curis EPS Results

• Actual EPS: -$4.02
• Consensus EPS: -$6.95
• Beat/Miss: Beat by +$2.93
• One Year Ago EPS: N/A

Curis Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $1.00 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Curis Announcement Details

• Quarter: Q2 2026
• Date: 8/14/2026
• Time: Before Market Opens
• Conference Call Date: Friday, August 14, 2026
• Conference Call Time: 4:00PM ET

Curis (NASDAQ:CRIS) is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development programs target molecular pathways involved in tumor growth, survival and immune regulation, with the goal of addressing cancers that have limited treatment options.

Curis’ lead investigational product is emavusertib, an orally administered inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies involving patients with hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain lymphomas. As an investigational medicine, emavusertib has not been established as safe or effective for any use unless approved by the applicable regulatory authorities.

Founded in 1997 and headquartered in Lexington, Massachusetts, Curis has historically advanced cancer therapies through internal research and strategic collaborations. Its earlier programs included hedgehog-pathway inhibitor vismodegib, which was developed with Genentech and later approved in the United States as Erivedge for certain advanced basal cell carcinomas. Curis also has a collaboration with Aurigene Discovery Technologies for the discovery and development of small-molecule oncology therapies. The company is led by President and Chief Executive Officer James E. Dentzer.